Feature | Implantable Cardioverter Defibrillator (ICD) | May 08, 2020

Head-to-head Comparison Shows Subcutaneous ICDs Safer Than Transvenous Defibrillators 

PRAETORIAN Trial is the first direct comparison of ICD devices and underscores benefits of the S-ICD with fewer device-related complications

The Boston Scientific Emblem MRI-safe S-ICD system does not require a transvenous lead, leading to fewer complications with this type of ICD.

The Boston Scientific Emblem MRI-safe S-ICD system does not require a transvenous lead, leading to fewer complications with this type of ICD.

May 8, 2020 — A new clinical trial is the first to compare the safety and efficacy of subcutaneous implantable cardioverter defibrillators (S-ICDs) to transvenous implantable cardioverter-defibrillators (TV-ICD). The prospective, randomized trial is the first of its kind to show S-ICDs are as protective as TV-ICDs in the prevention of sudden cardiac death, but have a better safety profile, which highlights the device as an important treatment option for patients in need of an implantable cardioverter defibrillator (ICD) without pacing indication. Findings of the multicenter PRAETORIAN trial[1] were presented today as late-breaking clinical science as part of Heart Rhythm Society (HRS) 2020 Science, and will soon be published in The New England Journal of Medicine.

Cardiac implantable electrophysiological devices (CIEDs) such as ICDs, are a common treatment for cardiac arrhythmias and prevention of sudden cardiac arrest, with over 300,000 individuals receiving the therapy in the U.S. alone every year.[2] Device-related issues, including lead complications, are a known problem related to TV-ICDs. For this reason, S-ICDs were designed to offer an additional treatment option that can overcome lead-related complications. There are no randomized, controlled trials comparing the two therapies to-date. The PRAETORIAN trial was designed to demonstrate the non-inferiority of the S-ICD compared to the TV-ICD, with respect to acute and long-term device-related complications and inappropriate shocks.

The PRAETORIAN trial is an investigator-initiated, international, multicenter, randomized, noninferiority trial. A total of 849 patients with a class I or IIa indication for ICD therapy and without the need for pacing, were randomized and followed until a median of four years. Of the patients, 426 patients were assigned to receive an S-ICD and 423 were assigned to a TV-ICD, with similar baseline characteristics in the two groups. The baseline characteristics are comparable to those of other major ICD trials, thereby showing that the trial reflects a general ICD population. The trial population was 20 percent female, with a median age of 63 years (55- 70 years), and 69 percent had ischemic cardiomyopathy with a median left ventricular ejection fraction of 30 percent (25-35 percent).

Results of the PRAETORIAN trial show that in a general ICD-population, the subcutaneous ICD is non-inferior to the transvenous ICD with regards to major ICD-related adverse events with significantly less lead-related complications in patients treated with the S-ICD. The primary end point of the trial was a composite of device-related complications and inappropriate shocks during a median follow-up of 4 years, and an upper 95 percent confidence limit of 1.45 for the hazard ratio of the primary end point was used to test for noninferiority. Secondary end points included death from any cause (including sudden cardiac death) and appropriate ICD therapy. These findings indicate that S-ICDs should be considered in all patients in need of an ICD without pacing indication.

“Having this side by side comparison of the two ICD therapies in a general ICD population for the first time can help guide clinicians toward eliminating device-related complications for this large patient population,” said lead author, Reinoud E. Knops, M.D., Ph.D., Academisch Medisch Centrum in Amsterdam. “As we look to generate informed decision making throughout the defibrillator field, we hope our study will provide crucial insight and help equip physicians with new long-term insights to help inform ICD selection.

Since the rate of most lead-related complications of TV-ICDs occur after more than four years, patient cohort of the PRAETORIAN study will be followed for another four years. The authors of the study also note that future results could reflect S-ICD updates that help prevent inappropriate shocks that may have occurred in earlier stages of the trial. 

Read more in the related HRS late-breaking presention UNTOUCHED Trial Data Underscores Safety And Efficacy Of Boston Scientific S-ICD System

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology
 

References:

1. Olde Nordkamp LR, Knops RE, Bardy GH, et al. Head-to-head Comparison Shows Subcutaneous ICDs Safer Than Transvenous Defibrillators. Am Heart J. 2012 May;163(5):753-760.e2. doi: 10.1016/j.ahj.2012.02.012.

2. Greenspon A.J., Patel J.D., Lau E., et al. (2011) 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 58:1001-1006.

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme